Epithelial-to-mesenchymal Transition and Drug Resistance: Transitioning Away from Death

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2019 Aug 3

PMID 31372302

Citations 17

Authors

Kyung-A Song

Anthony C Faber

Affiliations

Soon will be listed here.

Citing Articles

NINJ1 in Cell Death and Ferroptosis: Implications for Tumor Invasion and Metastasis.

Chen S, Shyu I, Chi J Cancers (Basel). 2025; 17(5).

PMID: 40075648 PMC: 11898531. DOI: 10.3390/cancers17050800.

Phenotypic Plasticity and Cancer: A System Biology Perspective.

Subbalakshmi A, Ramisetty S, Mohanty A, Pareek S, Do D, Shrestha S J Clin Med. 2024; 13(15).

PMID: 39124569 PMC: 11313222. DOI: 10.3390/jcm13154302.

Signaling dynamics in coexisting monoclonal cell subpopulations unveil mechanisms of resistance to anti-cancer compounds.

Blanchard C, Gomeiz A, Avery K, El Gazzah E, Alsubaie A, Sikaroodi M Cell Commun Signal. 2024; 22(1):377.

PMID: 39061010 PMC: 11282632. DOI: 10.1186/s12964-024-01742-3.

Diverse temporal and spatial mechanisms work, partially through Stanniocalcin-1, V-ATPase and senescence, to activate the extracellular ATP-mediated drug resistance in human cancer cells.

Zhang H, Song J, Ward R, Han Y, Hunt A, Shriwas P Front Oncol. 2024; 14:1276092.

PMID: 38380370 PMC: 10876858. DOI: 10.3389/fonc.2024.1276092.

Targeting HER3 to overcome EGFR TKI resistance in NSCLC.

Chen Q, Jia G, Zhang X, Ma W Front Immunol. 2024; 14:1332057.

PMID: 38239350 PMC: 10794487. DOI: 10.3389/fimmu.2023.1332057.

References

Zeisberg M, Neilson E . Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009; 119(6):1429-37. PMC: 2689132. DOI: 10.1172/JCI36183. View

Graham T, Yacoub R, Taliaferro-Smith L, Osunkoya A, Odero-Marah V, Liu T . Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells. Breast Cancer Res Treat. 2009; 123(1):139-47. PMC: 4100622. DOI: 10.1007/s10549-009-0623-7. View

Wellner U, Schubert J, Burk U, Schmalhofer O, Zhu F, Sonntag A . The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009; 11(12):1487-95. DOI: 10.1038/ncb1998. View

Thiery J, Acloque H, Huang R, Nieto M . Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139(5):871-90. DOI: 10.1016/j.cell.2009.11.007. View

Deep G, Agarwal R . Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev. 2010; 29(3):447-63. PMC: 3928361. DOI: 10.1007/s10555-010-9237-0. View

Sequist L, Waltman B, Dias-Santagata D, Digumarthy S, Turke A, Fidias P . Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011; 3(75):75ra26. PMC: 3132801. DOI: 10.1126/scitranslmed.3002003. View

Faber A, Corcoran R, Ebi H, Sequist L, Waltman B, Chung E . BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov. 2011; 1(4):352-65. PMC: 3229203. DOI: 10.1158/2159-8290.CD-11-0106. View

Katayama R, Shaw A, Khan T, Mino-Kenudson M, Solomon B, Halmos B . Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med. 2012; 4(120):120ra17. PMC: 3385512. DOI: 10.1126/scitranslmed.3003316. View

Ng K, Hillmer A, Chuah C, Juan W, Ko T, Teo A . A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012; 18(4):521-8. DOI: 10.1038/nm.2713. View

10.

Zhang Z, Lee J, Lin L, Olivas V, Au V, LaFramboise T . Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012; 44(8):852-60. PMC: 3408577. DOI: 10.1038/ng.2330. View

11.

Oliveras-Ferraros C, Corominas-Faja B, Cufi S, Vazquez-Martin A, Martin-Castillo B, Iglesias J . Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle. 2012; 11(21):4020-32. PMC: 3507497. DOI: 10.4161/cc.22225. View

12.

Ren J, Chen Y, Song H, Chen L, Wang R . Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line. J Cell Biochem. 2012; 114(6):1395-403. DOI: 10.1002/jcb.24481. View

13.

Bean G, Ganesan Y, Dong Y, Takeda S, Liu H, Chan P . PUMA and BIM are required for oncogene inactivation-induced apoptosis. Sci Signal. 2013; 6(268):ra20. PMC: 3753585. DOI: 10.1126/scisignal.2003483. View

14.

Costa C, Molina M, Drozdowskyj A, Gimenez-Capitan A, Bertran-Alamillo J, Karachaliou N . The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res. 2014; 20(7):2001-10. DOI: 10.1158/1078-0432.CCR-13-2233. View

15.

Niederst M, Benes C . EMT twists the road to PI3K. Cancer Discov. 2014; 4(2):149-51. PMC: 3918580. DOI: 10.1158/2159-8290.CD-13-1030. View

16.

Wilson C, Ye X, Pham T, Lin E, Chan S, McNamara E . AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs. Cancer Res. 2014; 74(20):5878-90. DOI: 10.1158/0008-5472.CAN-14-1009. View

17.

Wilson C, Nicholes K, Bustos D, Lin E, Song Q, Stephan J . Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition. Oncotarget. 2014; 5(17):7328-41. PMC: 4202126. DOI: 10.18632/oncotarget.2397. View

18.

Karachaliou N, Codony-Servat J, Teixido C, Pilotto S, Drozdowskyj A, Codony-Servat C . BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. Sci Rep. 2015; 5:17499. PMC: 4671004. DOI: 10.1038/srep17499. View

19.

Popper H . Progression and metastasis of lung cancer. Cancer Metastasis Rev. 2016; 35(1):75-91. PMC: 4821869. DOI: 10.1007/s10555-016-9618-0. View

20.

Li Y, Deutzmann A, Choi P, Fan A, Felsher D . BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia. Oncotarget. 2016; 7(19):26926-34. PMC: 5053622. DOI: 10.18632/oncotarget.8731. View